Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS316 for Sputum Induction in Interstitial Lung Disease
NCT01381666Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2003
- Primary completion
- Apr 2004
01
Overview
Phase 2, randomised trial of denufosol tetrasodium in sarcoidosis and interstitial lung disease (ILD) (2 arms), sponsored by Merck & Co. Primary endpoint: Diagnosis of sarcoidosis using sputum induction (sputum weight) at 60 minutes. Started Jan 2003; status: terminated.
02
Drugs
denufosol tetrasodium
03
Conditions
sarcoidosisinterstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT01381666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381666.